AbbVie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports
(Reuters) - AbbVie (NYSE:ABBV) is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen (NASDAQ:IMGN) and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter. The sale is expected to be announced as soon as Thursday, following fixed-income investor calls on Wednesday,...